Celera, Syrrx in Drug Discovery Partnership | GenomeWeb

NEW YORK, Dec. 12 – Celera Genomics and Syrrx said Wednesday they had formed a drug discovery research collaboration.

Structural genomics company Syrrx said it would use its technology for determining a protein’s structure to uncover the 3-D make-up of proteins Celera identifies as potential drug targets.

Celera said it would use the information generated through the collaboration to discover small molecule drugs. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.